Skip to main content
TipRanks
Go Ultimate75% OFF

Exelixis (EXEL) Drug Pipeline

3,215 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Zanzalintinib, Mk-34574, Xl092Colorectal CancerPhase IIINot Yet RecruitingZanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseAug 03, 2026
Zanzalintinib, Nivolumab, Cabozantinib, Enzalutamide, Atezolizumab, Prednisone, Abiraterone, Xl184, Xl092, CabometyxColorectal Cancer, Cancer, Prostate Cancer, Hepatocellular Carcinoma (Hcc), Renal Cell Carcinoma (Rcc), Non-Clear Cell Renal Cell Carcinoma (Nccrcc), Pancreatic Neuroendocrine Tumors (Pnet), Extra-Pancreatic Net (Epnet), Differentiated Thyroid Cancer (Dtc)Phase IIIEnrolling By InvitationLong-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyMay 27, 2026―
Belzutifan, Zanzalintinib, Xl092Carcinoma, Renal CellPhase IIIRecruitingA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Mar 20, 2026
Zanzalintinib, Xl092MeningiomaPhase IIRecruitingA Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaFeb 19, 2026
Belzutifan, Cabozantinib, ZanzalintinibRenal Cell CarcinomaPhase IIIRecruitingA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Nov 07, 2025
Xb371Solid TumorsPhase IRecruitingA Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid TumorsAug 08, 2025
Belzutifan, ZanzalintinibRenal Cell Carcinomaphase1AndPhase2RecruitingSubstudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)Jun 25, 2025
ZanzalintinibHepatic Impairment, Moderate Hepatic ImpairmentPhase IRecruitingPharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)Apr 30, 2025―
Xb628Solid Tumor, Metastatic Solid Tumor, Advanced Solid Tumor, Immune Sensitive TumorPhase IRecruitingA Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid TumorsApr 23, 2025―
Zanzalintinib, EverolimusPancreatic Neuroendocrine Tumor (Pnet), Extra-Pancreatic Neuroendocrine Tumor (Epnet)phase2AndPhase3RecruitingZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsApr 17, 2025

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Exelixis (EXEL) have in its pipeline
Exelixis EXEL is currently developing the following drugs: Zanzalintinib, Mk-34574, Xl092, Zanzalintinib, Nivolumab, Cabozantinib, Enzalutamide, Atezolizumab, Prednisone, Abiraterone, Xl184, Xl092, Cabometyx, Belzutifan, Zanzalintinib, Xl092, Zanzalintinib, Xl092, Belzutifan, Cabozantinib, Zanzalintinib, Xb371, Belzutifan, Zanzalintinib, Zanzalintinib, Xb628, Zanzalintinib, Everolimus, Xl495, Adc Cytotoxic Agents, Pembrolizumab, Xb010, Zanzalintinib, Nivolumab, Ab521, Zanzalintinib, Pembrolizumab, Olaparib, Xl309, Nivolumab, Xl092, Sunitinib Malate, Atezolizumab, Regorafenib, Xl092, Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Xl114, Bevacizumab, Nivolumab, Xb002, Fulvestrant, Prednisone, Abiraterone, Xl102, Docetaxel, Cabozantinib, Atezolizumab, Cabozantinib, Enzalutamide, Atezolizumab, Prednisone, Abiraterone Acetate, Xl184, Cabometyx, Cabozantinib, Atezolizumab, Docetaxel, Ramucirumab, Nivolumab, Ipilimumab, Cabozantinib, Lucitanib, Nivolumab, Ipilimumab, Cabozantinib, Xl184, Cabometyx, Daratumumab, Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin, Pembrolizumab, Capecitabine, Temozolomide, Pemetrexed, Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Rucaparib, Regorafinib, Enzalutamide, Sunitinib, Atezolizumab, Avelumab, Xl092, Cabozantinib, Atezolizumab, Sorafenib, Xl184, Cabometyx, Xl184, Cabometyx, Cabozantinib, Xl184, Cabometyx, Cabozantinib, Atezolizumab, Nivolumab, Ipilimumab, Cabozantinib, Sunitinib, Cabozantinib, Prednisone, Abiraterone, Cabozantinib Tablets, Cabozantinib 140 Mg, Cabozantinib 60 Mg, Cabozantinib Tablets, Everolimus Tablets, Cabozantinib, Prednisone, Cabozantinib, Prednisone, Mitoxantrone, Cabozantinib, Cdc7-Inhibitor. These drug candidates are in various stages of clinical development as the company works toward FDA approval.